Journal of Practical Oncology ›› 2020, Vol. 34 ›› Issue (6): 530-534.doi: 10.11904/j.issn.1002-3070.2020.06.009
• Review • Previous Articles Next Articles
LI Yunxue, WANG Gang, SUN Bei, ZUO Qian, WU Linfeng
Received:2020-03-16
Revised:2020-04-17
Online:2020-12-28
Published:2020-12-23
CLC Number:
LI Yunxue, WANG Gang, SUN Bei, ZUO Qian, WU Linfeng. Treatment attitude and the status of diagnosis and treatment in neck lymph nodes of papillary thyroid cancer[J]. Journal of Practical Oncology, 2020, 34(6): 530-534.
| 1 Haucen BR,Alexander EK,Bible KC,et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133. 2 Teixeira G,Teixeira T,Gubert F,et al.The incidence of central neck micrometastatic disease in patients with papillary thyroid cancer staged pre-operatively and intraoperatively as N0[J].Surgery,2011,150(6):1161-1167. 3 Kim SY,Kim BW,Pyo JY,et al.Macrometastasis in papillary thyroid cancer patients is associated with higher recurrence in lateral neck nodes[J].World J Surg,2018,42(1):123-129. 4 Fu JY,Wu Y,Wang ZY,et al.Clinical and pathological analysis of central compartment dissection in patients with papillary thyroid cancer with negative clinical lymph node metastasis[J].Zhonghua Wai Ke Za Zhi,2007,45(7):470-472. 5 Amin SN,Shinn JR,Naguib MM,et al.Risk factors and outcomes of postoperative recurrent well-differentiated thyroid cancer:a single institution′s 15-year experience[J].Otolaryngol Head Neck Surg,2020,162(4):469-475. 6 Mehanna H,AI-Maqbili T,Carter B,et al.Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma:A systematic review and meta-analysis of 21329 person-years of follow-up[J].J Clin Endocrinol Metab,2014,99(8):2834-2843. 7 Liu LS,Liang J,Li JH,et al.The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma:a meta-analysis[J].Eur Arch Otorhinolaryngol,2017,274(3):1327-1338. 8 Zhao W,You L,Hou X,et al.The effect of prophylactic central neck dissection on locoregional recurrence in papillary thyroid cancer after total thyroidectomy:a systematic review and meta-analysis :pCND for the locoregional recurrence of papillary thyroid cancer[J].Ann Surg Oncol,2017,24(8):2189-2198. 9 Liu H,Li Y,Mao Y,et al.Local lymph node recurrence after central neck dissection in papillary thyroid cancers:A meta analysis[J].Eur Ann Otorhinolaryngol Head Neck Dis,2019,136(6):481-487. 10Kim BY,Choi N,Kim SW,et al.Randomized trial of prophylactic ipsilateral central lymph node dissection in patients with clinically node negative papillary thyroid microcarcinoma[J].Eur Arch Otorhinolaryngol,2020,277(2):569-576. 11 Gui CY,Qiu SL,Peng ZH,et al.Clinical and pathologic predictors of central lymph node metastasis in papillary thyroid microcarcinoma:a retrospective cohort study [J].J Endocrinol Invest,2018,41(4):403-409. 12 Gu JH,Zhao YN,Xie RL,et al.Analysis of risk factors for cervical lymph node metastasis of papillary thyroid microcarcinoma:a study of 268 patients [J].BMC Endocr Disord,2019,19(1):124-124. 13 Adam MA,Pura J,Goffredo P,et al.Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer[J].J Clin Onco,2015,33(21):2370-2375. 14 Feng JW,Pan H,Wang L,et al.Total tumor diameter:the neglected value in papillary thyroid microcarcinoma[J].J Endocrinol Invest,2020,43(5):601-613. 15 Virk RK,Van Dyke AL,Finkelstein A,et al.BRAFV600E mutation in papillary thyroid microcarcinoma:a genotype-phenotype correlation[J].Modern Pathol,2012,26(1):62-70. 16 Yip L,Nikiforova MN,Yoo JY,et al.Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer:a study of 1510 patients[J].Ann Surg,2015,262(3):519-525. 17 Alzahrani AS,Xing M.Impact of lymph node metastases identified on central neck dissection(CND)on the recurrence of papillary thyroid cancer:potential role of BRAFV600E mutation in defining CND[J].Endocr Relat Cancer,2013,20(1),13-22. 18 Zheng X,Peng C,Gao M,et al.Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma:a study of 1,587 patients[J].Cancer Biol Med,2019,16(1):121-130. 19 Zhang L,Wei WJ,Ji QH,et al.Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma:a study of 1066 patients[J].J Clin Endocrinol Metab,2012,97(4):1250-1257. 20 Zhao HQ,Li H.Meta-analysis of ultrasound for cervical lymph nodes in papillary thyroid cancer:Diagnosis of central and lateral compartment nodal metastases.[J].Eur J Radiol,2019,112:14-21. 21 Wu X,Li B,Zheng C,et al.Risk factors for central lymph node metastases in patients with papillary thyroid microcarcinoma.[J].Endocr Pract,2018,24(12):1057-1062. 22 Abboud B,Smayra T,Jabbour H,et al.Correlations of neck ultrasound and pathology in cervical lymph node of papillary thyroid carcinoma[J].Acta Chir Belg,2019,25:1-7. 23 Horvath E,Majlis S,Rossi R,et al.An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management[J].J Clin Endocr Metab,2009,94(5):1748-1751. 24 Wémeau JL,Sadoul JL,d′Herbomez M,et al.Guidelines of the French Society of Endocrinology for the management of thyroid nodules [J].Ann Endocrinol(Paris),2011,72(4):251-281. 25 Shin JH,Baek JH,Chung J,et al.Ultrasonography diagnosis and imaging-based management of thyroid nodules:Revised Korean Society of Thyroid Radiology consensus statement and recommendations [J].Korean J Radiol,2016,17(3):370-395. 26 付鹏,陈文,崔立刚,等.2017美国放射学会甲状腺影像学报告与数据系统应用价值探索[J].北京大学学报(医学版),2019,51(6):1067-1070. 27 Frasoldati A,Toschi E,Zini M,et al.Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer[J].Thyroid,1999,9(2):105-111. 28 Frasoldati A,Valcavi R.Challenges in neck ultrasonography:Lymph-adenopathy and parathyroid glands[J].Endocrine Prac,2004,10(3):261-268. 29 Tseng FY,Hsiao YL,Chang TC.Cytologic features of metastatic papillary thyroid carcinoma in cervical lymph nodes[J].Acta Cytol,2002,46(6):1043-1048. 30 Pacini F,Fugazzola L,Lippi F,et al.Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses:A clue to the diagnosis of metastatic differentiated thyroid cancer[J].J Clin Endocrinol Metab,1992,74(6):1401-1404. 31 Lee MJ,Ross DS,Mueller PR,et al.Fine-needle biopsy of cervical lymph nodes in patients with thyroid cancer:A prospective comparison of cytopathologic and tissue marker analysis[J].Radiology,1993,187(3):851-854. 32 Jeong HS,Baek CH,Son YI,et al.Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma:comparison with ultrasound and contrast-enhanced CT[J].Clin Endocrinol(Oxf),2006,65(3):402-407. 33 Suh CH,Baek JH,Choi YJ,et al.Performance of CT in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid cancer:a systematic review and meta-analysis[J].Am J Neuroradiol,2017,38(1):154-161. 34 Kim BS,Kim SJ,Kim IJ,et al.Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma[J].Thyroid,2012,22(7):725-729. 35 Morita S,Mizoguchi K,Suzuki M,et al.The accuracy of(18)[F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography,ultrasonography,and enhanced computed tomography alone in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma[J].World J Surg,2010,34(11):2564-2569. 36 Chen Q,Raghavan P,Mukherjee S,et al.Accuracy of MRI for the diagnosis of metastatic cervical lymphadenopathy in patients with thyroid cancer[J].Radiol Med,2015,120(10):959-966. 37 Sancho JJ,Lennard TW,Paunovic I,et al.Prophylactic central neck disection in papillary thyroid cancer:a consensus report of the European Society of Endocrine Surgeons(ESES)[J].Langenbecks Arch Surg,2014,399(2):155-163. 38 高明.甲状腺结节和分化型甲状腺癌诊治指南[J].中国肿瘤临床,2012,39(17):1249-1272. 39 中国抗癌协会甲状腺癌专业委员会.甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J].中国肿瘤临床,2016,43(12):526-526. 40 Yoo HS,Shin MC,Ji YB,et al.Optimal extent of prophylactic central neck dissection for papillary thyroid carcinoma:Comparison of unilateral versus bilateral central neck dissection[J].Asian J Surg,2018,41(4):363-369. 41 Yoo BJ,Song CM,Ji YB,et al.Efficacy of central neck dissection for clinically node-negative papillary thyroid carcinoma:propensity scoring matching[J].Front Endocrinol,2019,10:172-172. 42 Raffaelli M,De Crea C,Sessa L,et al.Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral central neck dissection in patients with clinically node-negative papillary thyroid carcinoma[J].Surgery,2012,152(6):957-964. 43 Dobrinja C,Troian M,Cipolat Mis T,et al.Rationality in prophylactic central neck dissection in clinically node-negative(cN0)papillary thyroid carcinoma:Is there anything more to say? A decade experience in a single-center[J].Int J Surg,2017,41(Suppl 1):40-47. 44 Son YI,Jeong HS,Baek CH,et al.Extent of prophylactic lymph node dissection in the central neck area of the patients with papillary thyroid carcinoma:comparison of limited versus comprehensive lymph node dissection in a 2-year safety study[J].Ann Surg Oncol,2008,15(7):2020-2026. 45 孔繁巍,赵长久.分化型甲状腺癌碘131治疗后的外周血细胞改变[J].实用肿瘤学杂志,2018,32(5):476-479. 46 Hay ID,Hutchinson ME,Gonzalez-Losada T,et al.Papillary thyroid microcarcinoma:a study of 900 cases observed in a 60-year period[J].Surgery,2008,144(6):980-987. 47 Wang TS,Goffredo P,Sosa JA,et al.Papillary thyroid microcarcinoma:an over-treated malignancy[J].World J Surg,2014,38(9):2297-2303. 48 Momesso DP,Vaisman F,Yang SP,et al.Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive Iodine[J].J Clin Endocr Metab,2016,101(7):2692-2700. |
| [1] | GU Na, TAN Cheng, WANG Luyao, SHEN Hongsheng, LI Xijing, LI Xinyan, LIU Cuicui, ZHAO Xiumei. Effects of maytansine on proliferation,migration,invasion,apoptosis and autophagy of human thyroid cancer cells [J]. Journal of Practical Oncology, 2025, 39(1): 21-29. |
| [2] | CAO Wenyuan, LUO Xiaoting, HE Qian. Research progress of exosomal miRNA in Clinical diagnosis of lymph node metastasis in thyroid cancer [J]. Journal of Practical Oncology, 2023, 37(5): 434-438. |
| [3] | MA Jingyu, XIANG Zhisheng, LIN Yongtian, WEN Yeying, ZHOU Yan. Epidemic characteristics and changing trends of thyroid cancer in cancer registration areas of Fujian province from 2011 to 2020 [J]. Journal of Practical Oncology, 2023, 37(4): 301-307. |
| [4] | GAO Zhemin, LI Xiaoxue, HUO Kai, WANG Libin, CHEN Jing, LU Wenhui. Incidence time trend and survival analysis of thyroid cancer in Cangzhou urban area from 2010 to 2019 [J]. Journal of Practical Oncology, 2023, 37(3): 195-199. |
| [5] | ZHANG Hui, YAN Wang, SUN Minghua. Effects of arisaema decipiens volatile oil on the malignant biological behavior of thyroid cancer cells through a miR-762/NF2 axis [J]. Journal of Practical Oncology, 2023, 37(3): 207-214. |
| [6] | WU Nannan, YIN Ruili, SUN Rongxin, ZHAO Dong. The diagnostic value of FAM20A in thyroid cancer was analyzed based on bioinformatics methods [J]. Journal of Practical Oncology, 2023, 37(3): 230-235. |
| [7] | ZHAO Shengwen, WU Tong. Short-term efficacy and safety of 131I combined with apatinib in the treatment of differentiated thyroid cancer with lung metastasis [J]. Journal of Practical Oncology, 2022, 36(4): 323-326. |
| [8] | LIU Rui, CHEN Yang, SHI Qingping, YU Qiuli, ZHU Yunfang, WEN Hongmei. Characteristics and time trend of thyroid cancer incidence and mortality from 2012 to 2016 in cancer registration areas of Yunnan province [J]. Journal of Practical Oncology, 2021, 35(6): 489-494. |
| [9] | YU Youlin, YU Junlin, HU Chaohua, SHEN Xiongshan, LI Weimin, LU Ting, YANG Feng, YANG Qingqing, LIU Chenhao. Analysis for clinical prognostic value of LAYN in thyroid cancer and its influence on infiltration of immune cells [J]. Journal of Practical Oncology, 2021, 35(4): 357-364. |
| [10] | Zhang Guangyao, Guo Wei, Zhu Yitong, Ding Gaoheng, Zhu Gongjian, Wu Jianjun, Liu Yuqin. Epidemiological characteristics and trends of thyroid cancer in cancer registration areas of Gansu province,2009—2015 [J]. Journal of Practical Oncology, 2021, 35(3): 218-223. |
| [11] | LI Weiwei,ZHOU Jinyi,DONG Jianmei,MA Zhaojun,WU Ming,MIAO Weigang,LUO Pengfei,HAN Renqiang. Epidemic status of thyroid cancer in Jiangsu province in 2015 and its trend analysis from 2006 to 2015 [J]. Journal of Practical Oncology, 2021, 35(1): 1-6. |
| [12] | XU Zhiyong,MA Xiaoliang. Establishment of a nomogram model for predicting the risk of postoperative recurrence in patients with thyroid cancer [J]. Journal of Practical Oncology, 2021, 35(1): 35-40. |
| [13] | ZHOU Yan,GAO Rensheng,YAO Xiyu,MA Jingyu,LIN Yongtian,XIANG Zhisheng,JIANG Huijuan. Investigation and analysis of thyroid cancer incidence in Pingtan comprehensive experimental area of Fujian province,2013—2015 [J]. Journal of Practical Oncology, 2020, 34(3): 193-197. |
| [14] | LIU Guangxia, ZHAO Lianchun, CHEN Fang, JIA Qian, GAO Wei, HOU Zhan, LU Yamin. Effect and mechanism of ZCCHC12 on malignant transformation of thyroid cells [J]. Journal of Practical Oncology, 2020, 34(2): 133-138. |
| [15] | WU Dan, WANG Lu, WANG Xinghua, CUI Yali. Inhibitory effect and mechanism of 131I combined with apatinib on refractory thyroid cancer cells [J]. Journal of Practical Oncology, 2020, 34(2): 139-143. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||